Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
暂无分享，去创建一个
V. Baladandayuthapani | C. Cleeland | R. Orlowski | B. Amini | C. M. Stellrecht | V. Gandhi | S. Zaman | X. Wang | Z. Berková | Sheeba K. Thomas | J. Shah | D. Weber | R. Davis | Y. Lin | M. Fu | Muhamed Baljevic | Claudia Morales de Partovi | M. Baljevic